Literature DB >> 27198482

Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials.

Jonathan Rabinowitz1, Nomi Werbeloff2, Francine S Mandel2, François Menard2, Lauren Marangell2, Shitij Kapur2.   

Abstract

Several often-cited meta-analyses have reported that the efficacy of antidepressant medications depends on the severity of depression. They found that drug-placebo differences increased as a function of initial severity, which was attributed to decreased responsiveness to placebo among patients with severe depression rather than to increased responsiveness to medication. We retested this using patient-level data and also undertaking a meta-analysis of trial-level data from 34 randomised placebo controlled trials (n = 10 737) from the NEWMEDS registry. Although our trial-level data support prevous findings, patient-level data did not show any significant effect of initial depression severity on drug v. placebo difference. © The Royal College of Psychiatrists 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27198482     DOI: 10.1192/bjp.bp.115.173906

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

1.  Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis.

Authors:  Ramona Meister; Mariam Abbas; Jochen Antel; Triinu Peters; Yiqi Pan; Ulrike Bingel; Yvonne Nestoriuc; Johannes Hebebrand
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-12-08       Impact factor: 4.785

2.  Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?

Authors:  Stefan Leucht; S Z Levine; M Samara; A Cipriani; J M Davis; T A Furukawa
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-10       Impact factor: 5.270

3.  The severity of psychiatric disorders.

Authors:  Mark Zimmerman; Theresa A Morgan; Kasey Stanton
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

4.  Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.

Authors:  Katja Machmutow; Ramona Meister; Alessa Jansen; Levente Kriston; Birgit Watzke; Martin Christian Härter; Sarah Liebherz
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

5.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

6.  A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.

Authors:  George Salaminios; Larisa Duffy; Anthony Ades; Ricardo Araya; Katherine S Button; Rachel Churchill; Tim Croudace; Catherine Derrick; Padraig Dixon; Christopher Dowrick; Simon Gilbody; William Hollingworth; Vivien Jones; Tony Kendrick; David Kessler; Daphne Kounali; Paul Lanham; Alice Malpass; Tim J Peters; Derek Riozzie; Jude Robinson; Debbie Sharp; Laura Thomas; Nicky J Welton; Nicola Wiles; Glyn Lewis
Journal:  Trials       Date:  2017-10-24       Impact factor: 2.279

7.  Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.

Authors:  Ymkje Anna de Vries; Annelieke M Roest; Johannes G M Burgerhof; Peter de Jonge
Journal:  Depress Anxiety       Date:  2018-04-16       Impact factor: 6.505

8.  Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines.

Authors:  Martin Plöderl; Michael P Hengartner
Journal:  BMC Psychiatry       Date:  2019-09-02       Impact factor: 3.630

9.  The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.

Authors:  Gemma Lewis; Larisa Duffy; Anthony Ades; Rebekah Amos; Ricardo Araya; Sally Brabyn; Katherine S Button; Rachel Churchill; Catherine Derrick; Christopher Dowrick; Simon Gilbody; Christopher Fawsitt; William Hollingworth; Vivien Jones; Tony Kendrick; David Kessler; Daphne Kounali; Naila Khan; Paul Lanham; Jodi Pervin; Tim J Peters; Derek Riozzie; George Salaminios; Laura Thomas; Nicky J Welton; Nicola Wiles; Rebecca Woodhouse; Glyn Lewis
Journal:  Lancet Psychiatry       Date:  2019-09-19       Impact factor: 27.083

10.  The SMILES trial: do undisclosed recruitment practices explain the remarkably large effect?

Authors:  Marc L Molendijk; Eiko I Fried; Willem Van der Does
Journal:  BMC Med       Date:  2018-12-28       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.